Venus Remedies is currently trading at Rs. 291.30, up by 17.35 points or 6.33% from its previous closing of Rs. 273.95 on the BSE.
The scrip opened at Rs. 279.10 and has touched a high and low of Rs. 299.40 and Rs. 279.10 respectively. So far 49,000 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 358.05 on 15-May-2013 and a 52 week low of Rs. 196.95 on 26-Jul-2012.
Last one week high and low of the scrip stood at Rs. 282.00 and Rs. 263.00 respectively. The current market cap of the company is Rs. 283 crore.
The promoters holding in the company stood at 39.21% while Institutions and Non-Institutions held 13.27% and 47.52% respectively.
Venus Remedies has received patent from Mexico for its novel antibiotic Potentox which has been granted by the Mexican Institute of Industrial Property (IMPI), the patent protects the composition of Potentox. The patent provides an exclusivity period for Potentox up to 2025.
Besides, the drug is also protected by patents from various other countries, including USA, India, Australia, New Zealand, South Korea, South Africa, Canada and Ukraine. Further, to take this novel antibiotic adjuvant entity to Mexico, the company is already holding talks with some big pharmaceutical companies over there for strategic tie-ups.
Potentox is an antibiotic adjuvant entity (AAE), a drug effective to treat cases of hospital-acquired pneumonia and febrile neutropenia infections, primarily caused by quinolones or aminoglycoside-resistant microbes.
Venus Remedies is a pharmaceutical manufacturing company. The company provides formulations in area of antibiotics and oncological therapeutics. The company has two manufacturing facilities located in India and Germany. It manufactures Oncological and Cefelosporine Injectable products.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: